Inhibition of CYP2C19 and CYP3A4 by Omeprazole Metabolites and Their Contribution to Drug-Drug Interactions

Yoshiyuki Shirasaka; Jennifer E. Sager; Justin D. Lutz; Connie Davis; Nina Isoherranen

doi:10.1124/dmd.113.051722

Research ArticleArticle

Inhibition of CYP2C19 and CYP3A4 by Omeprazole Metabolites and Their Contribution to Drug-Drug Interactions

Yoshiyuki Shirasaka, Jennifer E. Sager, Justin D. Lutz, Connie Davis and Nina Isoherranen

Drug Metabolism and Disposition July 2013, 41 (7) 1414-1424; DOI: https://doi.org/10.1124/dmd.113.051722

Yoshiyuki Shirasaka

Department of Pharmaceutics, School of Pharmacy (Y.S., J.E.S., J.D.L., N.I.), and Division of Nephrology, Department of Medicine, School of Medicine (C.D.) University of Washington, Seattle, Washington; and Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Japan (Y.S.)

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jennifer E. Sager

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Justin D. Lutz

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Connie Davis

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Nina Isoherranen

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
eLetters
PDF + SI
PDF

Submit a Response to This Article

Compose eLetter

Title *

Contents

More information about text formats

Plain text

No HTML tags allowed.
Web page addresses and e-mail addresses turn into links automatically.
Lines and paragraphs break automatically.

Author Information

Contributors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Statement of Competing Interests

Competing interests? *

Yes

Please describe the competing interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.

PreviousNext

In this issue

Drug Metabolism and Disposition

Vol. 41, Issue 7

1 Jul 2013

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Editorial Board (PDF)
Front Matter (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Inhibition of CYP2C19 and CYP3A4 by Omeprazole Metabolites and Their Contribution to Drug-Drug Interactions

Message Subject (Your Name) has forwarded a page to you from Drug Metabolism & Disposition

Message Body (Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

Research ArticleArticle